Elsevier

The Lancet

Volume 339, Issue 8794, 14 March 1992, Pages 629-631
The Lancet

ORIGINAL ARTICLES
Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer

https://doi.org/10.1016/0140-6736(92)90792-2Get rights and content

Abstract

Attempts to prevent peritoneal carcinomatosis after surgery for gastric cancer by intraperitoneal administration of anticancer drugs have not been successful, largely because the drugs are not retained in the peritoneal cavity. We have assessed the prophylactic efficacy of a delayed-release preparation—mitomycin adsorbed onto activated charcoal (M-CH). 50 patients with gastric cancer and serosal infiltration were randomly assigned intraperitoneal treatment with M-CH (50 mg mitomycin intraoperatively) or no anticancer prophylaxis (control). Survival rates for the 3 years of follow-up were significantly higher among the 24 M-CH recipients (1 was lost to follow-up) than among the 25 controls (p<0·01). There were significant differences in survival between the groups at 1·5 years after randomisation (difference 34·6% [95% confidence interval 8·5-60·8%]; p<0·01) and at 2·0, 2·5, and 3·0 years (41·7% [14·2-69·1%]; p<0·005). The concentration of mitomycin was significantly higher in peritoneal exudate than in plasma for 24 h after drug administration. Side-effects were slight and well tolerated. Thus, peroperative intraperitoneal treatment with M-CH seems to improve survival after gastrectomy for gastric cancer, presumably by a prophylactic effect on peritoneal recurrence.

References (18)

  • Jb Dupont et al.

    Adenocarcinoma of the stomach: review of 1,497 cases

    Cancer

    (1978)
  • E. Yamada et al.

    The surgical treatment of cancer of the stomach

    Int Surg

    (1980)
  • I. Rusznyak et al.

    Absorption of water and crystalloid molecules from serous cavities

  • I. Rusznyak et al.

    Absorption of corpuscular particles from serous cavities

  • A. Hagiwara

    Mitomycin C adsorbed to activated carbon particles as a new drug dosage form for cancer chemotherapy [in Japanese]

    Akita J Med

    (1983)
  • A. Hagiwara et al.

    Selective delivery of high levels of mitomycin C to peritoneal carcinomatosis using a new dosage form

    Anticancer Res

    (1986)
  • A. Hagiwara et al.

    Chemotherapy for carcinomatous peritonitis with MMC-CH, mitomycin C adsorbed on activated carbon particles: clinical trials

    Cancer

    (1987)
  • A. Hagiwara et al.

    Intraoperative chemotherapy with carbon particles adsorbing mitomycin C for gastric cancer with peritoneal dissemination in rabbits

    Surgery

    (1988)
There are more references available in the full text version of this article.

Cited by (194)

  • Effect of intraperitoneal chemotherapy and peritoneal lavage in positive peritoneal cytology in gastric cancer. Systematic review and meta-analysis

    2016, European Journal of Surgical Oncology
    Citation Excerpt :

    For discrete variables: Odd Ratio (OR) were calculated for peritoneal recurrence rate outcome, Risk Ratio (RR) were calculated for mortality outcome. The fixed-effects and random-effects models were used to calculate the outcomes.17,18 Heterogeneity amongst the trials was determined by means of the Cochrane Q value and quantified using the I2 inconsistency test.

  • Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials

    2014, European Journal of Surgical Oncology
    Citation Excerpt :

    In the random-effects model, the 2-year mortality rate was significantly favourable to the surgery + IPC arm (OR = 0.16, 95%CI = 0.08–0.29). Three RCTs were included26,27,41 (Fig. 6). One study included patients with PC.27

  • Gastric Cancer

    2011, Current Problems in Cancer
    Citation Excerpt :

    After publication of the Intergroup 0116 data, 63.2% of potentially eligible patients did not receive chemoradiation therapy.39 Chemotherapy alone in the adjuvant setting has been studied in multiple trials using different agents, including mitomycin-c and anthracycline-based therapy, with some displaying survival benefit,40-54 and other studies not deriving benefit.55-61 Four meta-analyses62-65 of adjuvant chemotherapy vs surgery alone displayed conflicting results, with most negative, and the positive studies suffering from unusually low surgical control group survival.

  • Gastric cancer

    2009, Critical Reviews in Oncology/Hematology
  • Medicines for Cancer: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies

    2023, Medicines for Cancer: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies
View all citing articles on Scopus
View full text